The second ELRIG meeting on Therapeutic Oligonucleotides, scheduled for May 14-15, 2025, will be hosted at the AstraZeneca R&D site in Gothenburg. This dynamic event aims to build upon the success of the inaugural Therapeutic Oligonucleotides meeting and the well-regarded Advances in Cell-Based Assays in Drug Discovery. Esteemed scientists from academia, industry, and the vendor community will convene to explore the discovery, validation, and targeting of drug candidates using antisense oligonucleotides (ASOs) and siRNA. Our ambition is to establish an open-access meeting that fosters an inspiring environment for networking, encouraging collaboration between biologists and chemists across diverse research areas.
Oligonucleotide-based drugs, including ASOs and siRNAs, are already significantly impacting patients’ lives. The conference will delve into the nature of drug targets amenable to modulation by oligonucleotides, while comparing the advantages and limitations of these modalities with other drug types. Recent advancements in broadening their application, including innovative approaches to ensure their safety and efficacy, as well as the use of targeted delivery to reach disease-relevant tissues, will be covered. Success stories in bringing therapeutic oligonucleotides to the clinic will also be shared.